• Record revenue of US$803.8M, a 56% increase year-over-year
• FDA approval and CMS reimbursement of Gozellix®, a next generation PSMA-PET imaging agent
• Expansion of Illuccix® availability to global markets including Australia, Brazil, Canada, Europe, and the UK

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX) has announced its financial results for the year ended 31 December 2025. The company recorded an operating profit of $29,776,000, primarily driven by continued strong growth in U.S. sales of Illuccix and the launch of Gozellix. Total revenue for the year was $803,794,000, a 56% increase from the previous year. Operating expenditure totaled $408,397,000, including $171,249,000 related to R&D activities. The company secured FDA approval and reimbursement for Gozellix, launched new clinical programs, and delivered clinical data across multiple therapeutic programs. While the company faced challenges with Complete Response Letters for TLX250-Px (Zircaix®) and TLX101-Px (Pixclara®), it remains focused on remediation efforts. Telix has continued to invest in manufacturing infrastructure, including the acquisition of RLS Radiopharmacies, to support its long-term growth strategy as a vertically integrated radiopharmaceutical company. The company's pipeline now includes three active therapeutic pivotal trials in prostate, kidney, and brain cancer, setting the stage for future clinical milestones and the realization of the value in its theranostic pipeline.

The company generated total revenue of $803,794,000 for the 2025 financial year, a 56% increase from the previous year.

Telix remains strongly positioned for long-term growth, driven by scientific excellence and a commitment to improving patient outcomes worldwide. The company is focused on delivering its late-stage pipeline, growing its precision medicine business, building the next generation of products, and expanding its global infrastructure.